New Myeloma Imaging Guidelines Developed by Jens Hillengass, MD of Roswell Park
Posted: Jun 17, 2019
New Myeloma Imaging Guidelines Developed by Jens Hillengass, MD of Roswell Park image

Dr. Jens Hillengass, Chief of Myeloma at Roswell Park Comprehensive Cancer Center (Buffalo, NY), led the International Myeloma Working Group (IMWG) to organize new guidelines for imaging techniques to be more accurate when diagnosing myeloma patients, as well as other plasma-cell disorders. 

New treatment and drug strategies are significantly improving each year. These guidelines are the first of its kind in over a decade. 

“Use of newer imaging techniques is changing the whole landscape, from diagnosis to treatment to supportive care to survivorship, and all those things are coming into this direction of research in multiple myeloma right now,” --Jens Hillengass, MD

The updated imaging guidelines are derived from examining results of computed tomography (CT) and X-ray from several countries. Dr. Hillengass and his team discovered that "using only conventional X-ray misses 25% of instances where patients have bone destruction already", and therefore need immediate treatment and attention.

The major addition in the new guidelines is the use of whole-body low-dose CT instead of conventional skeletal survey as the standard for assessing bone destruction. In addition, the team recommends PET-CT (positron emission tomography) and MRI (magnetic resonance imaging) to be included in general clinical practices.

“There has to be destruction of 30 to 50% of the bone, sometimes up to 70%, before you see anything on X-ray,” says Hillengass. “More sophisticated imaging is necessary not only in the beginning to assess the disease but also to assess the response and to see what is left after our standard treatment. Myeloma is a disease that can cause focal and diffuse destruction of the bone, and to see that, you need sharp imaging.”

Dr. Hillengass hopes that the implication of these new techniques will lead to "more refined imaging, more accurate diagnoses, earlier treatments and more patients living longer due to lasting remissions."

Read the full press release on newswise.org.

 

The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Legend Biotechnologies
Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811